Loading
Every dated change on the records linked to Perivascular epithelioid cell tumour (PEComa), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Locally advanced unresectable or metastatic malignant PEComa
Objective response 39% (independent review), durable, enriched in TSC2-mutant tumours; FDA approval November 2021.
A milestone in how this cancer is treated.